- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioNTech SE (B1NT34)
Assess today's live BioNTech SE (B1NT34) share price, performance and insights using our live B3: B1NT34 stock exchange data.
Analyse the historical data and BioNTech SE share price performance charts on this page. Our technical summary section provides analysis on BioNTech SE share price buy/sell indicators using real-time data (or discuss the BioNTech SE (B1NT34) stock price today with other investors in the BioNTech SE BVMF share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current BVMF B1NT34 share price (ISIN: BRB1NTBDR005) to enhance your trading decisions with our free investment tools and resources.
What Is the BioNTech SE Share Price Today?
The BioNTech SE share price today is 30.82.
What Is the Stock Symbol for BioNTech SE
The stock symbol (or 'ticker') for BioNTech SE is "B1NT34."
What Stock Exchange Does BioNTech SE Trade On?
BioNTech SE is listed and trades on the B3 stock exchange.
Is BioNTech SE a Good Stock to Buy?
Determining whether BioNTech SE—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and BioNTech SE share price performance charts on this page. Our technical summary section provides analysis on BioNTech SE share price buy/sell indicators using real-time data (or discuss the BioNTech SE (B1NT34) stock price today with other investors in the BioNTech SE BVMF share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current BVMF B1NT34 share price (ISIN: BRB1NTBDR005) to enhance your trading decisions with our free investment tools and resources.
What Is the BioNTech SE Share Price Today?
The BioNTech SE share price today is 30.82.
What Is the Stock Symbol for BioNTech SE
The stock symbol (or 'ticker') for BioNTech SE is "B1NT34."
What Stock Exchange Does BioNTech SE Trade On?
BioNTech SE is listed and trades on the B3 stock exchange.
Is BioNTech SE a Good Stock to Buy?
Determining whether BioNTech SE—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
30.82
-1.73(-5.31%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.75
31.95
52 wk Range
25.78
43.61
B1NT34 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.7531.95
52 wk Range
25.7843.61
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
B1NT34 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 6K Biontech Se For: 13 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Earnings
Latest Release
10/03/2026
EPS / Forecast
-1.25 / --
Revenue / Forecast
907.4M / --
Compare B1NT34 to Peers and Sector
Metrics to compare | B1NT34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipB1NT34PeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.0x | 6.9x | −0.5x | |
PEG Ratio | 0.25 | 0.13 | 0.00 | |
Price/Book | 1.1x | 2.6x | 2.6x | |
Price / LTM Sales | 7.5x | 4.2x | 3.3x | |
Upside (Analyst Target) | - | 30.1% | 47.7% | |
Fair Value Upside | Unlock | 19.5% | 6.6% | Unlock |
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the BioNTech SE (B3: B1NT34) Share Price Today?
The BioNTech SE stock price today is 30.82 BRL.
What Stock Exchange Does BioNTech SE (B1NT34) Trade On?
BioNTech SE is listed and trades on the B3 Stock Exchange.
What Is the Ticker (Stock Symbol) for BioNTech SE?
The stock symbol (also called a 'ticker') for BioNTech SE is "B1NT34."
What Is the Current BioNTech SE Market Capitalisation?
As of today, BioNTech SE (B3: B1NT34) market cap is 124.40B BRL.
What Is BioNTech SE's (B1NT34) Earnings Per Share (TTM)?
The BioNTech SE EPS is currently -4.70 (Trailing Twelve Months).
Is B1NT34 a Buy or Sell From a Technical Analyst Perspective?
Based on today's BioNTech SE moving averages and other technical indicators, the daily buy/sell signal for B1NT34 stock is Neutral.
How Many Times Has BioNTech SE Stock Split?
BioNTech SE has split 1 times. (See the B1NT34 stock split history page for full effective split date and price information.)
How Many Employees Does BioNTech SE Have?
BioNTech SE has 7807 employees, based on their latest Companies House report.
What is the current trading status of BioNTech SE (B3: B1NT34)?
As of 04/05/2026, BioNTech SE (B1NT34) is trading at a share price of 30.82 BRL, with a previous close of 32.55 BRL. The stock has fluctuated within a day range of 30.75 BRL to 31.95 BRL, while its 52-week range spans from 25.78 BRL to 43.61 BRL.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.